🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Renaissance Technologies (RenTech)’s MAZE Holdings & Trades

First Buy
Q3 2025
Duration Held
3 Quarters
Largest Add
Q3 2025
+86,100 Shares
Current Position
15,800 Shares
$471,630 Value

Renaissance Technologies (RenTech)'s MAZE Position Overview

Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 15,800 shares of Maze Therapeutics, Inc. (MAZE) worth $471,630, representing 0.00% of the portfolio. First purchased in 2025-Q3, this short-term holding has been held for 3 quarters.

Based on 13F filings, Renaissance Technologies (RenTech) has maintained this position in MAZE for several quarters, showing initial confidence in the investment. Largest reduction occurred in Q4 2025, reducing 59,000 shares.

Analysis based on 13F filings available since 2013 Q2

Renaissance Technologies (RenTech)'s Maze Therapeutics (MAZE) Holding Value Over Time

Track share changes against reported price movement

Quarterly Maze Therapeutics (MAZE) Trades by Renaissance Technologies (RenTech)

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q1 2026 -11,300 Reduce 41.70% 15,800 $29.85
Q4 2025 -59,000 Reduce 68.52% 27,100 $41.43
Q3 2025 +86,100 New Buy 86,100 $25.93

Renaissance Technologies (RenTech)'s Maze Therapeutics Investment FAQs

Renaissance Technologies (RenTech) first purchased Maze Therapeutics, Inc. (MAZE) in Q3 2025, acquiring 86,100 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Renaissance Technologies (RenTech) has held Maze Therapeutics, Inc. (MAZE) for 3 quarters since Q3 2025.

Renaissance Technologies (RenTech)'s largest addition to Maze Therapeutics, Inc. (MAZE) was in Q3 2025, adding 86,100 shares worth $2.23 M.

According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 15,800 shares of Maze Therapeutics, Inc. (MAZE), valued at approximately $471,630.

As of the Q1 2026 filing, Maze Therapeutics, Inc. (MAZE) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.

Renaissance Technologies (RenTech)'s peak holding in Maze Therapeutics, Inc. (MAZE) was 86,100 shares, as reported at the end of Q3 2025.